MarketCapExport financials
Protalix BioTherapeutics (PLX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Protalix BioTherapeutics Financial Ratios 2025-2008 | PLX
Brief overview of Protalix BioTherapeutics's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
The latest available valuation ratios are P/E 54.67x (median 11.13x), EV/EBITDA 32.7x (median 21.49x), P/S 3.29x (median 1.95x). The current ratio basket stands about 60.3% above the five-year base, increasing sensitivity to weak reports.
The 1/P/E calculation produces a 1.8% earnings yield. It does not capture future growth or capital structure.
Returns on assets and capital are represented by ROE -13.7%, ROA -8%, ROCE -9.9%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Current PEG is 0.15x; the market pays comparatively little per unit of expected growth.
The cash conversion cycle lengthened from 33.5 days to 292 days, or 258.6 days. More cash is tied up in operations.
Overall picture
Protalix BioTherapeutics's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.
Annual Financial Ratios Protalix BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.3 | 54.7 | 11.1 | -6.2 | -1.3 | -19.6 | -2.8 | -2.3 | -1.1 | -2.1 | 1.4 | -6.2 | -14.6 | -39.3 | -12.6 | -175.9 | - | - | |
P/S |
3.3 | 3.0 | 1.4 | 2.0 | 1.0 | 2.0 | 0.9 | 1.8 | 4.7 | 6.7 | 18.5 | 12.3 | 35.1 | 13.3 | 55.0 | 767.9 | - | - |
EPS |
-0.1 | 0.0 | 0.1 | -0.3 | -0.6 | -0.2 | -1.2 | -1.8 | -6.4 | -0.3 | 0.6 | -0.3 | -0.3 | -0.1 | 0.4 | -0.4 | 0.4 | - |
EV (Enterprise Value) |
193 M | 171 M | 120 M | 142 M | 77.8 M | 204 M | 149 M | 138 M | 143 M | 90.8 M | 90.7 M | 265 M | 458 M | 487 M | 512 M | 5.14 B | -81.3 M | -42.6 M |
EBITDA per Share |
-0.05 | 0.07 | 0.17 | -0.25 | -0.44 | 0.14 | -0.613 | -1.2 | -2.63 | -3.08 | -2.24 | -2.38 | -2.55 | -0.933 | -3.89 | -0.37 | - | - |
EV/EBITDA |
-47.8 | 32.7 | 10.3 | -11.9 | -2.1 | 45.9 | -9.7 | -4.1 | -2.7 | -2.4 | -3.6 | -9.0 | -16.3 | -47.7 | -13.2 | -171.5 | 2.5 | - |
PEG |
0.15 | -0.34 | -0.07 | 0.05 | 0.01 | 0.48 | -0.09 | -0.03 | 0.01 | 0.01 | 0.0 | 0.93 | 0.11 | 0.3 | -0.06 | - | - | - |
P/B |
3.6 | 3.7 | 2.8 | -8.7 | -6.1 | -4.7 | -0.7 | -1.2 | -2.9 | -6.2 | 7.4 | -3.3 | -15.0 | -136.1 | -17.7 | -450.5 | - | - |
P/CF |
-14.5 | 18.5 | -70.2 | -3.7 | -3.6 | -4.9 | -2.5 | -7.3 | -8.2 | -1.9 | -3.3 | -6.2 | -12.4 | -318.9 | -15.8 | -132.6 | - | - |
ROE % |
-13.69 | 6.79 | 24.76 | 140.29 | 456.96 | 24.13 | 25.99 | 50.03 | 272.51 | 294.92 | 533.77 | 53.85 | 103.13 | 346.08 | 140.08 | 256.10 | -197.95 | - |
ROA % |
-8.02 | 3.99 | 9.84 | -26.76 | -37.44 | -9.60 | -40.26 | -43.28 | -118.09 | -35.70 | 59.68 | -38.16 | -24.52 | -14.76 | -70.51 | -44.80 | - | - |
ROCE % |
-9.85 | 8.20 | 26.89 | -55.72 | -50.54 | -14.62 | -205.42 | -53.97 | -73.50 | -206.82 | -27.52 | -48.23 | -31.30 | -22.98 | -110.33 | -65.39 | -201.28 | - |
Current Ratio |
2.4 | 2.4 | 1.7 | 0.8 | 0.9 | 0.7 | 0.8 | 2.1 | 2.8 | 1.1 | 7.6 | 2.5 | 3.7 | 2.4 | 1.7 | 0.9 | - | - |
DSO |
40.7 | 28.0 | 27.5 | 30.8 | 25.9 | 19.4 | 31.4 | 50.4 | 32.6 | 27.5 | - | 45.4 | 66.3 | 15.0 | 226.8 | 192.7 | - | - |
DIO |
317.6 | 302.3 | 284.7 | 323.8 | 346.4 | 356.5 | 273.2 | 336.2 | 187.7 | 228.0 | 2883.5 | 268.8 | 535.1 | 181.0 | 14.7 | 49.5 | - | - |
DPO |
66.2 | 180.7 | 252.7 | 267.4 | 338.9 | 433.6 | 217.6 | 204.5 | 180.2 | 174.2 | 1814.5 | 159.3 | 353.3 | 236.1 | 660.9 | 261.2 | - | - |
Operating Cycle |
358.2 | 330.3 | 312.1 | 354.5 | 372.3 | 375.9 | 304.6 | 386.6 | 220.4 | 255.5 | 2883.5 | 314.2 | 601.4 | 196.0 | 241.5 | 242.2 | - | - |
Cash Conversion Cycle |
292.0 | 149.6 | 59.5 | 87.2 | 33.5 | -57.7 | 87.0 | 182.2 | 40.1 | 81.3 | 1069.0 | 154.9 | 248.1 | -40.1 | -419.4 | -18.9 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Protalix BioTherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | 0.23 | - | 0.03 | - | -0.05 | - | 0.04 | -0.03 | -0.06 | - | -0.03 | 0.29 | -0.05 | - | -0.07 | -0.11 | -0.05 | - | -0.09 | -0.25 | -0.14 | - | -0.14 | -0.13 | 0.1 | 0.02 | -0.24 | -0.52 | -0.5 | -0.4 | -0.04 | -0.06 | -0.5 | - | -0.09 | - | -0.48 | - | -0.07 | -0.11 | -0.09 | - | -0.04 | -0.05 | -0.06 | - | -0.09 | -0.07 | 0.08 | - | -0.06 | -0.07 | 0.05 | - | 0.06 | 0.11 | 0.07 | - | -0.1 | -0.16 | 0.06 |
EBITDA per Share |
0.01 | 0.27 | - | - | - | -0.05 | - | - | - | -0.06 | - | - | - | -0.04 | - | -0.05 | -0.11 | -0.03 | - | -0.02 | -0.19 | -0.09 | - | -0.05 | -0.05 | 0.29 | 0.15 | -0.02 | -0.34 | -0.35 | -0.25 | -0.02 | -0.04 | - | - | -0.05 | -0.08 | -0.05 | - | -0.05 | -0.09 | -0.07 | - | -0.03 | -0.05 | -0.05 | - | -0.04 | -0.04 | -0.06 | - | -0.06 | -0.07 | -0.05 | - | -0.06 | 0.11 | -0.07 | - | -0.1 | -0.16 | - |
ROE % |
32.40 | 24.02 | -3.23 | 6.75 | -5.41 | -21.16 | -13.16 | -18.00 | 21.61 | -281.30 | -265.87 | -234.89 | -176.11 | -195.16 | 115.46 | -1855.91 | -2179.54 | -2271.23 | -2301.77 | -2285.36 | -298.65 | -12.15 | 25.59 | 25.18 | 13.83 | 9.49 | 25.99 | 36.68 | 41.68 | 46.67 | 50.03 | 78.58 | 66.99 | 251.78 | 238.09 | 311.31 | 381.48 | 469.36 | 268.56 | 233.43 | 113.58 | -50.35 | -136.70 | -122.29 | -76.15 | -16.30 | 38.62 | 59.95 | 70.92 | 75.95 | 62.74 | 225.95 | -82.60 | 67.90 | 51.86 | 85.90 | -24.82 | 281.77 | 105.90 | 34.03 | 52.49 | 19.37 |
ROA % |
21.17 | 16.07 | -1.83 | 3.43 | -1.84 | -4.16 | 0.73 | 22.61 | 12.65 | 15.05 | 15.05 | 8.76 | 2.08 | -23.13 | -18.43 | -23.46 | -27.56 | -24.09 | -20.74 | -27.28 | -28.36 | -15.51 | -10.19 | -9.55 | -10.86 | -21.81 | -40.26 | -49.79 | -50.66 | -47.44 | -43.28 | -50.23 | -40.90 | -108.96 | -97.12 | -105.98 | -103.34 | -114.42 | -32.51 | -36.44 | -32.79 | -25.74 | -15.28 | -25.49 | -29.36 | -33.51 | -27.37 | -32.44 | -28.26 | -24.28 | -14.92 | -21.88 | -4.56 | -6.02 | -2.21 | -19.34 | -38.81 | -60.81 | -53.31 | -17.13 | -26.42 | -9.75 |
ROCE % |
36.21 | 25.54 | -2.67 | 8.01 | -2.75 | -21.21 | -12.85 | -17.11 | 3.47 | 3.68 | 19.98 | 6.04 | -8.31 | -45.23 | -38.21 | -42.84 | -105.56 | -103.84 | -98.18 | -84.25 | -67.54 | -16.20 | 0.70 | 42.87 | -0.66 | -124.66 | -205.42 | -257.86 | -238.72 | -145.65 | -53.97 | -59.40 | -70.79 | -64.81 | -50.41 | -91.87 | -138.11 | -165.30 | -152.44 | -158.25 | -123.28 | -67.61 | -18.57 | -30.44 | -35.05 | -40.94 | -34.68 | -41.19 | -37.27 | -31.96 | -19.59 | -30.08 | -5.41 | -8.90 | -3.79 | -30.26 | -61.65 | -95.02 | -83.57 | -26.48 | -41.88 | -15.22 |
Current Ratio |
2.4 | 2.9 | 2.4 | 2.8 | 2.8 | 2.6 | 1.7 | 2.1 | 1.4 | - | 0.8 | 1.8 | 1.8 | 1.0 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 | 1.2 | 0.7 | 0.7 | 0.7 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 0.9 | 0.9 | 0.9 | 1.1 | 1.1 | 1.1 | 1.1 | 0.6 | 0.6 | 0.6 | 0.6 | 0.8 | 0.8 | 0.8 | 0.8 | 1.0 | 1.0 | 1.0 | 1.0 | 0.7 | 0.7 | 0.7 | 0.7 |
DSO |
34.3 | 7.9 | - | 61.0 | 41.1 | 44.9 | - | 31.3 | 34.3 | 55.8 | - | 57.3 | 7.0 | 28.0 | - | 34.3 | 41.3 | 26.5 | - | 29.9 | 49.2 | 26.6 | - | 16.9 | 16.6 | 14.1 | - | 30.1 | 35.0 | 41.2 | - | 650.9 | 215.1 | 64.6 | - | 20.9 | 24.7 | 38.1 | - | 13.5 | 35.8 | 46.6 | - | 156.2 | 62.0 | 99.8 | - | 73.8 | 70.9 | 27.1 | - | 83.5 | 84.3 | 44.8 | - | 34.5 | 4.9 | 32.9 | - | 110.8 | 164.1 | - |
DIO |
436.8 | 571.7 | - | 232.3 | 315.9 | 215.0 | - | 206.6 | 100.0 | 294.6 | - | 384.3 | 296.4 | 548.8 | - | 200.4 | 369.5 | 261.2 | - | 349.6 | 265.6 | 258.5 | - | 416.2 | 653.4 | 282.8 | - | 232.2 | 276.1 | 373.1 | - | 407.9 | 358.2 | 255.9 | - | 117.8 | 129.4 | 285.8 | - | 112.7 | 285.7 | 960.6 | - | 2359.8 | 2338.8 | 1491.4 | - | 338.4 | 379.0 | 163.8 | - | 457.5 | 550.9 | 563.7 | - | 155.7 | 112.4 | 149.2 | - | 115.7 | 192.9 | - |
DPO |
74.2 | 97.5 | - | 66.1 | 84.0 | 47.1 | - | 212.0 | 93.3 | 102.8 | - | 347.7 | 175.5 | 257.0 | - | 81.5 | 165.9 | 112.3 | - | 179.4 | 120.5 | 194.4 | - | 229.8 | 360.6 | 254.7 | - | 184.9 | 219.9 | 374.1 | - | 248.1 | 217.8 | 226.6 | - | 113.1 | 124.3 | 328.1 | - | 86.1 | 218.3 | 832.3 | - | 1485.0 | 1471.8 | 1687.6 | - | 200.5 | 224.6 | 103.1 | - | 302.1 | 363.8 | 494.4 | - | 203.1 | 146.6 | 356.0 | - | 2087.1 | 3478.6 | - |
Operating Cycle |
- | - | - | 293.3 | 357.0 | 235.7 | - | 237.9 | - | - | - | 441.6 | 303.3 | 576.8 | - | 234.7 | 410.9 | 287.8 | - | 379.4 | 314.8 | 285.1 | - | 433.1 | 670.0 | 296.9 | - | 262.3 | 311.1 | 414.3 | - | 1058.8 | 573.3 | 320.6 | - | 138.7 | 154.1 | 323.9 | - | 126.2 | 321.5 | 1007.2 | - | 2516.0 | 2400.9 | 1591.2 | - | 412.2 | 449.9 | 190.9 | - | 541.0 | 635.2 | 608.4 | - | 190.3 | 117.3 | 182.2 | - | 226.5 | 357.0 | - |
Cash Conversion Cycle |
- | - | - | 227.2 | 273.0 | 103.5 | - | 25.8 | - | - | - | 93.9 | 127.8 | 414.6 | - | 153.2 | 244.9 | 175.4 | - | 200.0 | 194.3 | 90.7 | - | 203.4 | 309.4 | 42.2 | - | 77.4 | 91.2 | 40.2 | - | 810.7 | 355.5 | 94.0 | - | 25.6 | 29.9 | -4.2 | - | 40.1 | 103.2 | 174.9 | - | 1031.0 | 929.1 | -96.5 | - | 211.7 | 225.3 | 87.8 | - | 238.9 | 271.4 | 114.1 | - | -12.8 | -29.2 | -173.8 | - | -1860.7 | -3121.6 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Protalix BioTherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
Irlanda
Israel
Britain
Schweiz
